Genmab A/S (OTCMKTS:GNMSF - Get Free Report) announced its earnings results on Wednesday. The company reported $5.70 earnings per share for the quarter, beating the consensus estimate of $0.46 by $5.24, Zacks reports. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.
Genmab A/S Price Performance
Shares of GNMSF stock traded up $5.17 during mid-day trading on Tuesday, hitting $216.14. The stock had a trading volume of 512 shares, compared to its average volume of 4,891. Genmab A/S has a fifty-two week low of $186.61 and a fifty-two week high of $323.02. The company's 50-day simple moving average is $206.14 and its 200-day simple moving average is $228.78. The firm has a market cap of $14.28 billion, a PE ratio of 20.78 and a beta of 1.04.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
